In contrast to, e.g., CD19-directed CAR T gene therapy, which targets a very well-defined protein expressed on cancer cells and B cells [5], TEG001 is targeting metabolic changes in stressed and malignant cells, driven by a dysregulated mevalonate pathway [11]. The gene discussed is CD19; the disease is cancer.